Resveratrol: The Longevity Molecule Explained
Resveratrol launched the modern longevity supplement market and then spent fifteen years failing to live up to it. A clear-eyed account of the mechanism, the bioavailability problem and the evidence.
The Short Answer
Resveratrol is a stilbene polyphenol found in grape skin, red wine and Japanese knotweed that became the most famous longevity compound of the 2000s after being reported as a sirtuin activator. Two decades of subsequent work have complicated that story considerably: the direct sirtuin activation was largely an artefact of the assay used, oral bioavailability is extremely poor because the compound is conjugated almost immediately in the gut wall and liver, and human trials at 150 mg to 1,000 mg per day have produced small and inconsistent metabolic effects. It remains a genuinely interesting molecule with a plausible mechanism through AMPK signalling. It is not the intervention its early reputation promised.
Why Resveratrol Became Famous
In 2003, a screen for small molecules that activate SIRT1 identified resveratrol as the strongest hit. SIRT1 was already established as a regulator of gene expression, mitochondrial biogenesis and metabolic adaptation, and it was known to mediate part of the response to caloric restriction. A cheap plant compound that switched on the caloric restriction pathway was an extraordinary proposition, and it arrived alongside the observation that red wine consumption tracked with cardiovascular outcomes in French populations. The narrative wrote itself.
Subsequent work found that the apparent activation depended on a fluorophore attached to the assay substrate. With native substrates, resveratrol does not directly activate SIRT1 in the way originally reported. That correction did not eliminate the compound's biological activity, but it removed the clean mechanistic story that made it famous.
The Mechanism as Currently Understood
The best-supported account is indirect. Resveratrol inhibits several phosphodiesterases, which raises cyclic AMP, which activates AMPK. AMPK is the cell's low-energy sensor: when it is active, it promotes mitochondrial biogenesis through PGC-1 alpha, increases fatty acid oxidation, and suppresses mTOR signalling. NAD+ availability rises as a downstream consequence, which then increases sirtuin activity without resveratrol having touched a sirtuin directly.
Resveratrol also acts as a weak phytoestrogen, modulates NF-kB inflammatory signalling, and behaves as a hormetic stressor at moderate concentrations. That last property is worth holding onto, because it predicts something the trials later confirmed: the dose response may not be monotonic, and more is not automatically better.
The Bioavailability Problem
Resveratrol is absorbed well and then almost entirely inactivated before it reaches circulation. Sulfation and glucuronidation in the intestinal wall and liver convert the great majority of an oral dose into conjugates within minutes. Plasma concentrations of free trans-resveratrol after a typical supplemental dose are in the low nanomolar range, while the concentrations used in the cell experiments that generated the mechanistic story are typically micromolar, a difference of roughly a thousandfold.
Three counterarguments exist and each has partial support. The conjugates may act as a reservoir, with tissue enzymes releasing free resveratrol locally. The metabolites may have activity of their own. And the gut microbiome may convert resveratrol into compounds such as dihydroresveratrol with their own effects, which would make individual microbiome composition a determinant of response.
None of this rescues the original assumption that swallowing resveratrol delivers resveratrol to tissues at concentrations resembling the laboratory work. It does not.
What Human Trials Have Found
Resveratrol has been tested in metabolic populations, in older adults, in athletes and in cardiovascular cohorts, at doses from 75 mg to 5,000 mg per day and durations from four weeks to a year.
Metabolic markers
Meta-analyses of trials in people with impaired glucose handling have found modest reductions in fasting glucose and in insulin resistance indices, with the clearest effects in participants who started from a compromised metabolic baseline. Trials in metabolically healthy participants have generally found nothing.
Vascular measures
Small trials report improvements in flow-mediated dilation, a measure of endothelial function, particularly acutely after dosing. Longer trials with harder endpoints have not confirmed a sustained effect.
The exercise interference finding
A trial in older men found that resveratrol at 250 mg per day blunted several of the adaptations to an exercise training programme, including improvements in blood pressure, lipids and vascular function, relative to placebo. The proposed explanation is that exercise adaptation depends partly on transient oxidative stress, and that a compound with antioxidant and hormetic properties can interfere with the signal the body is responding to. Similar interference has been reported for high-dose vitamin C and E around training. This finding has not been consistently replicated, but it is a specific, mechanistically coherent reason for caution around the training window, and it points to a general principle worth more attention than resveratrol itself.
Dose, Form and Practical Considerations
Trans-resveratrol is the biologically relevant isomer. Cis-resveratrol, formed by light exposure, is not, so product handling and packaging matter. Standardised extracts state trans-resveratrol content specifically; extracts sold on total resveratrol content are less informative.
- 150 to 250 mg per day. The range used in most positive metabolic trials, typically taken with a fat-containing meal, which increases absorption.
- 500 mg to 1,000 mg per day. Common in commercial products and used in trials, with no consistent evidence of greater benefit than lower doses.
- 2,500 mg and above. Associated with gastrointestinal effects in a substantial fraction of participants, without corresponding benefit.
Micronised and piperine-combined formats increase measured plasma exposure. Whether that increased exposure translates into a larger functional effect has not been established, because the trials showing improved pharmacokinetics are not the trials with functional endpoints.
Safety and Interactions
At doses up to about 1,000 mg per day, resveratrol is generally well tolerated, with loose stools and abdominal discomfort as the most common effects. Higher doses produce gastrointestinal effects reliably.
The interaction profile deserves respect. Resveratrol inhibits several cytochrome P450 enzymes, including CYP3A4, which metabolises a large share of prescription medication, so it can raise circulating concentrations of other drugs. It has mild antiplatelet activity, which is relevant alongside anticoagulant or antiplatelet therapy and before surgery. Its weak oestrogenic activity is a reason for anyone with a hormone-sensitive condition to seek clinical input. And the exercise finding argues for separating it from the training window if it is in a stack alongside a serious training programme.
An Honest Position on Resveratrol
Resveratrol is the clearest case study in the longevity field of how a compelling mechanism becomes a market before the human evidence arrives, and of what happens when the evidence then arrives and is unremarkable. That history is more useful than the compound.
The defensible position today is narrow. There is reasonable support for small metabolic effects in people with impaired glucose handling, taken with fat, at moderate doses. There is little support for benefit in healthy adults, a specific reason for caution around training, and a real interaction profile. Pterostilbene, its dimethylated relative, has better bioavailability and is often preferred on that basis, though it carries less human outcome data, so the trade is greater exposure to a less-studied molecule.
If resveratrol is in a stack, it should be there for a stated reason with a defined review point, not because it was the first longevity compound anyone heard of.
The AEONNN Perspective
Resveratrol is a useful test of whether a recommendation system is honest. A naive engine trained on popularity would rank it near the top of any longevity stack. AEONNN weights the Evidence and Meta-Consensus layers against the Mechanistic layer rather than letting mechanism stand in for outcome, and resveratrol is a compound where those layers disagree. The output reflects the disagreement instead of hiding it.
It maps across Cellular Energy and Repair, Metabolic and Cardiovascular Health, and the Longevity meta-Pillar, which is exactly why it needs contextual reasoning rather than a fixed score. For a member with impaired glucose handling and no interacting medication, it is a plausible candidate. For a member in a hard training block, the exercise interference finding is directly relevant. For a member on medication metabolised by CYP3A4, the Safety layer removes it from consideration before anything else is weighed.
Contingency handles the case that the compound illustrates best: a protocol that fits a training phase may need to change when the phase does. That is the temporal logic the Shield architecture is designed to formalise.
Pillar Matrix mapping
Cellular Energy and Repair, Metabolic and Cardiovascular Health, Longevity and Biological Age
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Pharmacokinetics Layer (HMDB, PubChem)
- Safety Layer (DrugBank, FAERS)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
Does resveratrol actually activate sirtuins?
Not directly, in the way originally reported. The initial finding depended on a fluorophore-tagged assay substrate. Resveratrol does appear to increase sirtuin activity indirectly, by inhibiting phosphodiesterases, raising cyclic AMP, activating AMPK and increasing NAD+ availability.
How much resveratrol should be taken?
Positive metabolic trials have mostly used 150 to 250 mg per day of trans-resveratrol with a fat-containing meal. Doses above 1,000 mg per day have not shown greater benefit and cause gastrointestinal effects more often.
Is resveratrol from red wine meaningful?
No. A glass of red wine contains roughly one to two milligrams of resveratrol, orders of magnitude below trial doses, and comes with alcohol, which works against most longevity objectives on its own.
Why would resveratrol interfere with exercise?
Exercise adaptation depends partly on transient oxidative stress acting as a signal. A trial in older men found resveratrol blunted several training adaptations, consistent with similar findings for high-dose antioxidant vitamins. The result has not been consistently replicated but is a reasonable basis for separating it from the training window.
Is pterostilbene better than resveratrol?
Pterostilbene has substantially better oral bioavailability and a longer half-life due to its methylated structure. It also has far less human outcome data. The trade is more exposure to a less-studied compound.
Does resveratrol interact with medication?
Yes. It inhibits several cytochrome P450 enzymes including CYP3A4, which metabolises a large fraction of prescription drugs, and it has mild antiplatelet activity. Anyone on prescription therapy should have the interaction checked before use.
Is trans-resveratrol different from resveratrol?
Trans-resveratrol is the biologically active isomer. Light exposure converts it to the cis form, which is not. Products should specify trans-resveratrol content rather than total resveratrol.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.